Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
paper
Cited
Public
Unavailable
- Authors
- Haberl, Michael; Anwald, Birgit; Klein, Kathrin; Weil, Regina; Fuss, Christine; Gepdiremen, Akçahan; Zanger, Ulrich M; Meyer, Urs A; Wojnowski, Leszek
- Year
- 2005
- Journal
- Pharmacogenetics and genomics
- PMID
- 16041240
- DOI
- 10.1097/01.fpc.0000171517.22258.f1
The human cytochrome P450 2A6 (CYP2A6) enzyme metabolizes several xenobiotic compounds of clinical or toxicological importance. We aimed to identify genetic variants and major CYP2A6 haplotypes associated with CYP2A6 phenotypic variation. CYP2A6 mRNA level, protein level, activity and haplotypes were determined in Caucasian liver samples via real-time polymerase chain reaction, Western blot, coumarin 7-hydroxylation, DNA sequencing and genotyping, respectively. Phenotypes were then analyzed for associations with haplotypes. CYP2A6 transcript, protein and activity levels were correlated among each other. In 45 African-American, 156 Caucasian, 47 Chinese, 50 Japanese and 47 Korean DNA samples, we detected 95 different polymorphisms in the CYP2A6 gene, 49 of which had not been described previously. Caucasian variants formed 33 haplotypes which built four clades. Allele *9B and the CYP2A7/2A6 partial deletion allele CYP2A6*12B were both associated with decreased expression. The latter haplotype extends at least over 147 kb up into the CYP2B6 gene. A haplotype almost identical to allele *1A was associated with decreased expression and activity of CYP2A6 compared to all other haplotypes. In summary A CYP2A6*1A-like allele, *9B and *12B are major genetic determinants of CYP2A6 phenotype variation in Caucasians.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. | Dong T et al. | — | 2024 | → |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | — | 2024 | → |
| Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data. | Langlois AWR et al. | — | 2023 | → |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | — | 2023 | → |
| Pharmacogenetic Variation in Neanderthals and Denisovans and Implications for Human Health and Response to Medications. | Wroblewski TH et al. | — | 2023 | → |
| Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. | Jones SK et al. | — | 2022 | → |
| Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine. | Ahire D et al. | — | 2022 | → |
| Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression. | Tremmel R et al. | — | 2020 | → |
| How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing? | Carvalho Henriques B et al. | — | 2020 | → |
| Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. | Claw KG et al. | — | 2020 | → |
| Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? | De T et al. | — | 2019 | → |
| Nicotine-<i>N</i>'-Oxidation by Flavin Monooxygenase Enzymes. | Perez-Paramo YX et al. | — | 2019 | → |
| Biosignature Discovery for Substance Use Disorders Using Statistical Learning. | Baurley JW et al. | — | 2018 | → |
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | Olfson E et al. | — | 2018 | → |
| P450 Pharmacogenetics in Indigenous North American Populations. | Henderson LM et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | — | 2018 | → |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | López-Flores LA et al. | — | 2017 | → |
| Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. | Hosono H et al. | — | 2017 | → |
| Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity. | Park SL et al. | — | 2016 | → |
| Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. | Patel YM et al. | — | 2016 | → |
| Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes. | Zhang HF et al. | — | 2016 | → |
| Associations Between Genetic Ancestries and Nicotine Metabolism Biomarkers in the Multiethnic Cohort Study. | Wang H et al. | — | 2015 | → |
| CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers. | Hosono H et al. | — | 2015 | → |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | — | 2015 | → |
| Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. | Achour B et al. | — | 2014 | → |
| Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations. | Tiong KH et al. | — | 2014 | → |
| Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. | Chenoweth MJ et al. | — | 2014 | → |
| Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). | Chen LS et al. | — | 2014 | → |
| A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. | Bloom AJ et al. | — | 2013 | → |
| Advances in molecular modeling of human cytochrome P450 polymorphism. | Martiny VY et al. | — | 2013 | → |
| Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. | Djordjevic N et al. | — | 2013 | → |
| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. | Zanger UM et al. | — | 2013 | → |
| Determination of nicotine absorption from multiple tobacco products and nicotine gum. | Digard H et al. | — | 2013 | → |
| Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression. | Rieger JK et al. | — | 2013 | → |
| Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. | Saladores PH et al. | — | 2013 | → |
| Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. | Martis S et al. | — | 2013 | → |
| Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis. | Wassenaar CA et al. | — | 2013 | → |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | — | 2013 | → |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | — | 2012 | → |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | — | 2012 | → |
| Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. | Precht JC et al. | — | 2012 | → |
| Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. | Bloom AJ et al. | — | 2012 | → |
| Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. | Wang H et al. | — | 2011 | → |
| Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. | Lee IS et al. | — | 2011 | → |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | — | 2011 | → |
| Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22. | Tiong KH et al. | — | 2010 | → |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | — | 2010 | → |
| Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. | Al Koudsi N et al. | — | 2010 | → |
| Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. | Elens L et al. | — | 2010 | → |
| UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. | Berg JZ et al. | — | 2010 | → |
| Cytochrome P4502A6 stability in a mini organ culture model of human nasal mucosa for genotoxicology studies as detected by flow cytometry. | Kleinsasser NH et al. | — | 2009 | → |
| Genome-wide and candidate gene association study of cigarette smoking behaviors. | Caporaso N et al. | — | 2009 | → |
| Molecular genetics of nicotine metabolism. | Mwenifumbo JC et al. | — | 2009 | → |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | — | 2009 | → |
| Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology. | Koontz DA et al. | — | 2009 | → |
| Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies. | Lee AS et al. | — | 2008 | → |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | — | 2008 | → |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | — | 2008 | → |
| Regulatory polymorphisms and their contribution to interindividual differences in the expression of enzymes influencing drug and toxicant disposition. | Hines RN et al. | — | 2008 | → |
| Revealing the paradox of drug reward in human evolution. | Sullivan RJ et al. | — | 2008 | → |
| CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients? | Farinola N et al. | — | 2007 | → |
| Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. | Ring HZ et al. | — | 2007 | → |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | — | 2007 | → |
| Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. | Desta Z et al. | — | 2007 | → |
| Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. | Saussele T et al. | — | 2007 | → |
| Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. | Al Koudsi N et al. | — | 2006 | → |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | — | 2006 | → |
| Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. | Lamba JK et al. | — | 2006 | → |